Catalent Stock Today

CTLT -  USA Stock  

USD 130.89  1.84  1.39%

Catalent is selling for under 130.89 as of the 26th of October 2021; that is -1.39 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 130.56. Catalent has less than a 12 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for Catalent are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of September 2021 and ending today, the 26th of October 2021. Click here to learn more.
 Market Performance
12 of 100
  Odds Of Distress
Less than 12
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey. The company has 170.34 M outstanding shares of which 2.01 M shares are currently shorted by private and institutional investors with about 3.27 trading days to cover. More on Catalent

Catalent Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Catalent's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Catalent or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Latest headline from simplywall.st: It Looks Like Shareholders Would Probably Approve Catalent, Inc.s CEO Compensation Package - Simply Wall St
Catalent Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Catalent SEC Filings
Catalent SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameCatalent
ChairmanJohn Chiminski  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Obamacare Repeal
Average Analyst Recommendation
Analysts covering Catalent report their recommendations after researching Catalent's financial statements, talking to executives and customers, or listening in on Catalent's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Catalent. The Catalent consensus assessment is calculated by taking the average forecast from all of the analysts covering Catalent.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Catalent based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Catalent financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 6 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares167.7 M170.3 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted138.3 M170 M
Significantly Down
Increasing
Slightly volatile
Net Cash Flow from Operations366.1 M433 M
Fairly Down
Increasing
Slightly volatile
Total Assets7.5 B9.1 B
Significantly Down
Increasing
Slightly volatile
Total Liabilities4.5 B4.8 B
Notably Down
Increasing
Slightly volatile
Current Assets3.1 B2.9 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities971 M1.2 B
Significantly Down
Increasing
Slightly volatile
Total Debt3.2 B3.2 B
Fairly Down
Increasing
Slightly volatile
Return on Average Assets0.04950.062
Significantly Down
Increasing
Slightly volatile
Gross Margin0.310.338
Significantly Down
Decreasing
Stable
Asset Turnover0.480.469
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Catalent's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Financial Strength
Catalent's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Catalent's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Catalent's financial leverage. It provides some insight into what part of Catalent's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Catalent's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Catalent deploys its capital and how much of that capital is borrowed.
Liquidity
Catalent cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 3.33 B in liabilities with Debt to Equity (D/E) ratio of 0.78, which is about average as compared to similar companies. Catalent has a current ratio of 2.39, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

366.09 MillionShare
Catalent (CTLT) is traded on New York Stock Exchange in USA. It is located in 14 Schoolhouse Road, Somerset, NJ 08873, United States and employs 17,300 people. Catalent is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 22.54 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Catalent's market, we take the total number of its shares issued and multiply it by Catalent's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Catalent conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 170.34 M outstanding shares of which 2.01 M shares are currently shorted by private and institutional investors with about 3.27 trading days to cover. Catalent currently holds about 967 M in cash with 433 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66.
Check Catalent Probability Of Bankruptcy
Ownership
Catalent holds a total of one hundred seventy million three hundred fourty thousand outstanding shares. The majority of Catalent outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalent to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalent. Please pay attention to any change in the institutional holdings of Catalent as this could imply that something significant has changed or about to change at the company. Also note that nearly five million one hundred ten thousand two hundred invesors are currently shorting Catalent expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Catalent Ownership Details

Catalent Stock Price Odds Analysis

What are Catalent's target price odds to finish over the current price? Attributed to a normal probability distribution, the odds of Catalent jumping above the current price in 90 days from now is about 40.98%. The Catalent probability density function shows the probability of Catalent stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Catalent has a beta of 0.5107 suggesting as returns on the market go up, Catalent average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Catalent will be expected to be much smaller as well. Additionally, the company has an alpha of 0.1685, implying that it can generate a 0.17 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 130.89HorizonTargetOdds Up 130.89 
58.82%90 days
 130.89 
40.98%
Based on a normal probability distribution, the odds of Catalent to move above the current price in 90 days from now is about 40.98 (This Catalent probability density function shows the probability of Catalent Stock to fall within a particular range of prices over 90 days) .

Catalent Historical Income Statement

Catalent Income Statement is one of the three primary financial statements used for reporting Catalent's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Catalent revenue and expense. Catalent Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Catalent Direct Expenses is comparatively stable at the moment as compared to the past year. Catalent reported Direct Expenses of 2.65 Billion in 2020. Consolidated Income is likely to gain to about 631.2 M in 2021, whereas Net Loss Income from Discontinued Operations is likely to drop (92.4 K) in 2021. View More Fundamentals

Catalent Stock Against Markets

Picking the right benchmark for Catalent stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Catalent stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Catalent is critical whether you are bullish or bearish towards Catalent at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Catalent without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module

Catalent Corporate Directors

Catalent corporate directors refer to members of a Catalent board of directors. The board of directors generally takes responsibility for the Catalent's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Catalent's board members must vote for the resolution. The Catalent board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Bruce McEvoy - DirectorProfile
Peter Zippelius - Independent DirectorProfile
James Quella - DirectorProfile
Donald Morel - Independent DirectorProfile
Continue to Trending Equities. Note that the Catalent information on this page should be used as a complementary analysis to other Catalent's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Catalent Stock analysis

When running Catalent price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Catalent's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalent. If investors know Catalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Catalent is measured differently than its book value, which is the value of Catalent that is recorded on the company's balance sheet. Investors also form their own opinion of Catalent's value that differs from its market value or its book value, called intrinsic value, which is Catalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalent's market value can be influenced by many factors that don't directly affect Catalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalent's value and its price as these two are different measures arrived at by different means. Investors typically determine Catalent value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.